NEW YORK, Nov. 29, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Nivalis Therapeutics, Inc. ("Nivalis" or the "Company") (NASDAQ: NVLS). Such investors can obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/nvls.
The investigation concerns whether Nivalis and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On November 28, 2016, Nivalis announced that its Phase 2 Trial of Cavosonstat was unsuccessful in meeting its primary endpoint to indicate a benefit in the absolute change in percent-predicted FEV1 (lung function) or in sweat chloride reduction at 12 weeks, compared to the placebo. Following this news, Nivalis stock dropped roughly 59% on intraday trading on November 29, 2016.
If you are aware of any facts relating to this investigation, or purchased Nivalis shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/nvls. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.